Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francois Mercier

Showing results (21-30 of 43) with videos related to

Pageof 5
Sort By:
CPT: Pharmacometrics & Systems Pharmacology|October 17, 2025
Building Hybrid Pharmacometric-Machine Learning Models in Oncology Drug Development: Current State and RecommendationsAnna Fochesato, Logan Brooks, Omid Bazgir, et al.
Cancer Chemotherapy and Pharmacology|May 12, 2018
Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancerPeter N Morcos, Eveline Nueesch, Felix Jaminion, et al.
Radiation Protection Dosimetry|May 6, 2014
A report on radioactivity measurements of fish samples from the west coast of CanadaJing Chen, Michael W Cooke, Jean-Francois Mercier, et al.
British Journal of Cancer|February 10, 2023
Support to early clinical decisions in drug development and personalised medicine with checkpoint inhibitors using dynamic biomarker-overall survival modelsRené Bruno, Pascal Chanu, Matts Kågedal, et al.
Cancer Chemotherapy and Pharmacology|July 30, 2016
Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baselineLaurent Claret, Jenny Zheng, Francois Mercier, et al.
British Journal of Clinical Pharmacology|November 17, 2020
Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIOEkaterina Gibiansky, Claire Petry, Francois Mercier, et al.
Investigational New Drugs|January 19, 2021
Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumorsGeorgina Meneses-Lorente, Darren Bentley, Elena Guerini, et al.
Cancer Chemotherapy and Pharmacology|March 8, 2023
Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerationsGeorgina Meneses-Lorente, Elena Guerini, Francois Mercier, et al.
The Journal of Biological Chemistry|July 26, 2002
Beta 1/beta 2-adrenergic receptor heterodimerization regulates beta 2-adrenergic receptor internalization and ERK signaling efficacyCatherine Lavoie, Jean-Francois Mercier, Ali Salahpour, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|February 15, 2023
Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple SclerosisStephen L Hauser, Amit Bar-Or, Martin S Weber, et al.
Pageof 5

Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
CPT: Pharmacometrics & Systems Pharmacology|October 17, 2025
Building Hybrid Pharmacometric-Machine Learning Models in Oncology Drug Development: Current State and RecommendationsAnna Fochesato, Logan Brooks, Omid Bazgir, et al.
Cancer Chemotherapy and Pharmacology|May 12, 2018
Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancerPeter N Morcos, Eveline Nueesch, Felix Jaminion, et al.
Radiation Protection Dosimetry|May 6, 2014
A report on radioactivity measurements of fish samples from the west coast of CanadaJing Chen, Michael W Cooke, Jean-Francois Mercier, et al.
British Journal of Cancer|February 10, 2023
Support to early clinical decisions in drug development and personalised medicine with checkpoint inhibitors using dynamic biomarker-overall survival modelsRené Bruno, Pascal Chanu, Matts Kågedal, et al.
Cancer Chemotherapy and Pharmacology|July 30, 2016
Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baselineLaurent Claret, Jenny Zheng, Francois Mercier, et al.
British Journal of Clinical Pharmacology|November 17, 2020
Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIOEkaterina Gibiansky, Claire Petry, Francois Mercier, et al.
Investigational New Drugs|January 19, 2021
Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumorsGeorgina Meneses-Lorente, Darren Bentley, Elena Guerini, et al.
Cancer Chemotherapy and Pharmacology|March 8, 2023
Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerationsGeorgina Meneses-Lorente, Elena Guerini, Francois Mercier, et al.
The Journal of Biological Chemistry|July 26, 2002
Beta 1/beta 2-adrenergic receptor heterodimerization regulates beta 2-adrenergic receptor internalization and ERK signaling efficacyCatherine Lavoie, Jean-Francois Mercier, Ali Salahpour, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|February 15, 2023
Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple SclerosisStephen L Hauser, Amit Bar-Or, Martin S Weber, et al.
Pageof 5